MARKET

SLXN

SLXN

Silexion Therapeutics Corp
NASDAQ
1.310
-0.190
-12.67%
After Hours: 1.310 0 0.00% 18:37 11/20 EST
OPEN
1.400
PREV CLOSE
1.500
HIGH
1.400
LOW
1.280
VOLUME
15.74K
TURNOVER
--
52 WEEK HIGH
777.12
52 WEEK LOW
1.260
MARKET CAP
850.88K
P/E (TTM)
-0.0019
1D
5D
1M
3M
1Y
5Y
1D
Silexion Therapeutics Secures Continued Nasdaq Listing Approval
TipRanks · 1d ago
12 Health Care Stocks Moving In Wednesday's After-Market Session
Benzinga · 2d ago
Weekly Report: what happened at SLXN last week (1109-1113)?
Weekly Report · 4d ago
Silexion Q3 Net Loss Narrows To $2.5 Mln; First Patient Dosed In SIL204 Phase 2/3 Trial
NASDAQ · 11/13 17:56
Silexion Therapeutics GAAP EPS of -$13.70
Seeking Alpha · 11/13 16:31
*Silexion Therapeutics 3Q Net $2.53M >SLXN
Dow Jones · 11/13 14:04
Press Release: Silexion Therapeutics Reports -2-
Dow Jones · 11/13 14:03
Silexion Therapeutics Completes 1-for-24 Reverse Share Split
TipRanks · 11/12 21:40
More
About SLXN
Silexion Therapeutics Corp is an Israel-based oncology-focused biotechnology company. The Company is engaged in development of treatments for unsatisfactorily treated solid tumor cancers, which have the mutated KRAS oncogene. The KRAS gene is an oncogene that is involved in regulation of cell division as a result of its ability to relay external signals to the cell nucleus. Based on its research of refractory solid tumor cancers, it is developing a platform focused on the silencing of the KRAS oncogene using ribonucleic acid (RNA)-interference therapeutics. Its lead product candidate, SIL-204B, consists of locally administered small interfering RNAs (siRNA), in an extended-release formulation, as a preferred treatment of locally advanced pancreatic cancer patients, in combination with standard-of-care chemotherapy. Its clinical-stage pipeline is focused on treatment for pancreatic cancer (PC) tumors bearing the KRAS G12D or KRAS G12V mutations where metastases have not been detected.

Webull offers Silexion Therapeutics Corp stock information, including NASDAQ: SLXN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SLXN stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading SLXN stock methods without spending real money on the virtual paper trading platform.